Sequoia Capital-backed Chinese biopharma firm BrightGene has collected 521 million yuan ($75 million) in its initial public offering on the Shanghai Stock Exchange (SSE), according to a statement on Friday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
